tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Jonathan Demchick, 12 are a HOLD (63.16%), 4 are a BUY (21.05%), 3 are a SELL (15.79%).
Analyst Jonathan Demchick, currently employed carries an average stock price target met ratio of 85.71% that have a potential upside of 8.87% achieved within 279 days. Previously, Jonathan Demchick worked at MORGAN STANLEY.
Jonathan Demchick’s has documented 34 price targets and ratings displayed on 4 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on NUVA, NuVasive at 04-Aug-2023.
Analyst best performing recommendations are on GMED (GLOBUS MEDICAL).
The best stock recommendation documented was for NUVA (NUVASIVE) at 5/31/2023. The price target of $40 was fulfilled within 12 days with a profit of $1.84 (4.82%) receiving and performance score of 4.02.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Hold
15 days ago
(07-Nov-2024)
2/3 (66.67%)
$10.44 (17.24%)
115
Buy
$88
$6.9 (8.51%)
$78
16 days ago
(06-Nov-2024)
8/9 (88.89%)
$7.85 (9.79%)
266
Buy
$100
$18.9 (23.30%)
$75
16 days ago
(06-Nov-2024)
8/12 (66.67%)
$19.85 (24.77%)
268
Buy
$100
$18.9 (23.30%)
$80
16 days ago
(06-Nov-2024)
14/19 (73.68%)
$19.85 (24.77%)
224
Buy
$92
$10.9 (13.44%)
$70
16 days ago
(06-Nov-2024)
7/8 (87.5%)
$11.85 (14.78%)
127
What Year was the first public recommendation made by Jonathan Demchick?
